Obsidian Therapeutics, Inc.
corporate_fare Company Profile
Obsidian Therapeutics, Inc. (NASDAQ:OBX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for OBX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for OBX spans 8-K/A, 8-K.
Recent high-impact activity:
- Obsidian Files Merger Financials: $350M PIPE Alleviates Going Concern
- Obsidian Therapeutics finalizes reverse merger with Galera, secures $350M PIPE, and debuts on Nasdaq as OBX
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 253,084 shares in OBX as of the September 15, 2026 settlement, a 210.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 97.0% of OBX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OBX, detected from its recent SEC filings.
29.2M PIPE Shares Registered for Resale · Selling Stockholders Identified
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →